Log In
BCIQ
Print this Print this
 

PRLX 93936

  Manage Alerts
Collapse Summary General Information
Company Prolexys Pharmaceuticals Inc.
DescriptionCytotoxic small molecule that targets cells expressing mutated RAS oncoprotein
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today